Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.

Bicycle Health announced a partnership with Albertsons Companies to make prescriptions of buprenorphine injections available to patients. The buprenorphine extended-release injections, known as ...

An injectable form of buprenorphine, sold under the brand name Sublocade, provides patients with a month’s worth of addiction treatment. Oral versions of the drug must be taken every day. (Jenny ...

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...

Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more ...

Evidence demonstrates that SUBLOCADE supports long-term recovery from opioid use disorder (OUD) and is effective and safe. Publications highlight the importance of overcoming access barriers to ...

Rates of non-fatal overdose events following SUBLOCADE treatment was lower compared to daily opioid agonist therapy. Data published in the Journal of Addition Medicine Given the naturalistic, ...

Malachi Castner, 23, said he didn’t always sleep on the Blue Line train to avoid the cold and rain. He didn’t always start his day early by shooting up. He was once a teenager on his high school’s ...

Sublocade (buprenorphine) is a brand-name extended-release injection that’s prescribed for opioid use disorder. Sublocade has interactions with alcohol, some other drugs, and certain supplements.

Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) These FDA ...